Health Ministry Sets Ethical Standards for Commercial Use of Medical Samples

The Union Health Ministry has released guidelines for the ethical use of leftover, de-identified, and anonymous samples from diagnostic or surgical procedures for commercial purposes. These specimens include organs, tissues, cells, blood products, urine, saliva, DNA/RNA, hair, and nail clippings. Sources for these samples can be patients, autopsy specimens, tissue banks, IVF clinics, and organ donation centres.

After clinical and laboratory testing is completed for patients, hospitals often have large quantities of leftover samples. These are usually discarded as biomedical waste or biohazards needing proper disposal. Hospitals typically lack the capacity to store these samples after patient care is provided.

Commercial Interest and Ethical Guidelines

Commercial companies are interested in procuring these de-identified samples to develop diagnostic kits, identify disease markers, and advance innovations. The guidelines highlight that these samples can significantly contribute to research and development activities. However, hospitals must ensure that the samples are completely anonymous and de-identified irreversibly.

According to the guidelines, robust data security measures must protect any residual information associated with the samples. Companies should maintain transparent communication with relevant institutions and hospitals. The guidelines also stress that commercial kits and technologies developed should be affordable to ensure broader accessibility for patients and healthcare providers in India.

Informed Consent and Patient Rights

The guidelines state that patients own their biological samples and data collected. Institutions act as custodians on their behalf. As per ICMR National Ethical Guidelines 2017, informed consent is required for any secondary use of samples for research. However, if the clinical samples are anonymous or de-identified irreversibly after clinical care, they lose identity.

In such cases where leftover samples are de-identified and cannot be traced back to patients, a waiver of informed consent may be permitted. The guidelines assure that there would be no loss to patients' rights or autonomy since the samples cannot be traced back to them.

Regulatory Compliance

Companies must adhere to local, national, and international regulations governing the collection, storage, and secondary use of biological samples. This includes obtaining necessary approvals like ethical clearance and establishing formal agreements such as MoUs/MoA and MTAs. Any deviation or violation of regulations may result in action by government regulatory agencies through appellate bodies like the High Court or Supreme Court.

The guidelines emphasize that de-identified samples containing clinical information could still become identifiable, potentially breaching patient confidentiality. If the samples are identified or coded in a way that they can be traced back to the patient or contain clinical/personal information, these guidelines will not apply.

The Union Health Ministry's new guidelines aim to balance ethical considerations with the potential benefits of using leftover biological samples for research and development. By ensuring anonymity and robust data security measures, these guidelines seek to protect patient rights while fostering advancements in medical science.